Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-62.26	-61.43	-36.31	-27.71	-9.19
Depreciation & Amortization	0.67	0.5	0.37	0.34	0.15
Loss (Gain) From Sale of Assets	0.19	0.05	0.14	-	-
Asset Writedown & Restructuring Costs	0.74	0.74	-	-	-
Stock-Based Compensation	7.73	7.63	2.89	1.76	0.23
Other Operating Activities	1.63	1.03	0.15	0.63	0.13
Change in Accounts Receivable	-	-	-	1.16	-1.29
Change in Accounts Payable	-0.24	0.52	-0.63	1.01	0.46
Change in Other Net Operating Assets	-1.72	3.54	-0.07	2.42	0.26
Operating Cash Flow	-53.27	-47.42	-33.45	-20.39	-9.26
Capital Expenditures	-0.53	-2.08	-0.47	-0.73	-0.68
Investing Cash Flow	-0.53	-2.08	-0.47	-0.73	-0.68
Long-Term Debt Issued	-	1.25	-	9.83	-
Net Debt Issued (Repaid)	10.73	1.25	-	9.83	-
Issuance of Common Stock	0.4	137.77	0.18	0.04	0.01
Other Financing Activities	-1.18	-3.33	-2.05	-0.34	-0.21
Financing Cash Flow	9.94	135.69	68.13	43.79	31.69
Foreign Exchange Rate Adjustments	-0.02	-0.01	-0.01	-0.02	-0.05
Net Cash Flow	-43.89	86.18	34.2	22.64	21.7
Free Cash Flow	-53.8	-49.5	-33.92	-21.13	-9.94
Free Cash Flow Margin	-	-	-	-	-4734.29%
Free Cash Flow Per Share	-1.99	-2.01	-9.09	-6.13	-4.12
Cash Interest Paid	1.48	1	0.91	-	-
Levered Free Cash Flow	-36.61	-32.29	-23.45	-12.3	-
Unlevered Free Cash Flow	-35.22	-31.44	-22.6	-12.3	-
Change in Working Capital	-1.97	4.06	-0.7	4.58	-0.57

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q